




Product Information

Carboplatin - ADCARB

- **Indication** – Carboplatin is used as initial chemotherapy of
 - 1. Advanced **ovarian** carcinoma in combination with other approved chemotherapeutic agents .
 - 2. Carboplatin is used as palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy including patients who have been previously treated with cisplatin
- **Dosage Form** –Injection
- **Strengths** - 150 / 450 mg
- **Packaging** - vials

ADCARB
Carboplatin 150mg / 450mg Inj.




Carboplatin - ADCARB



➤ Dosage for Carboplatin Injection

- Carboplatin is used in recurrent ovarian carcinoma at a dosage of 360 mg/m² IV on day 1 every 4 weeks. In the chemotherapy of advanced **ovarian cancer**,
- In previously untreated patients carboplatin injection is administered in 300 mg/m² IV on day 1 every 4 weeks for 6 cycles, or cyclophosphamide 600 mg/m² IV on day 1 every 4 weeks for 6 cycles.

ADCARB
Carboplatin 150mg / 450mg Inj.



Factors Affecting Dosage

Kidney Function

Carboplatin is eliminated from the body through the kidneys, so patients with impaired kidney function may require lower doses.

1

Patient's Age

Older patients may require lower doses of carboplatin due to the increased risk of side effects.

2

3

Patient's Weight

Heavier patients may require higher doses of carboplatin due to their larger body size.

Docetaxel - ADOXI



Indication – Docetaxel is a microtubule inhibitor indicated for:

1. **Breast Cancer (BC):** single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC .
2. **Non-Small Cell Lung Cancer (NSCLC):** single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC .
3. **Hormone Refractory Prostate Cancer (HRPC):** with prednisone in androgen

Dosage Form – Injection

Strengths – 80 / 120 mg

Packaging -Vial



Docetaxel - ADOXI

Dosage of Docetaxel:

Breast Cancer :

- Local advanced or metastatic : Monotherapy: 60-100 mg/m² IV over 1 hour every 3 weeks :
- Operable node-positive: Adjuvant combination therapy: 75 mg/m² IV 1 hour after doxorubicin and cyclophosphamide every 3 weeks for 6 cycles

Non-small Cell Lung Cancer: 75 mg/m² IV over 1 hour every 3 weeks

Gastric Cancer :

- Day 1: 75 mg/m² IV infusion over 1 hour, followed by cisplatin 75 mg/m² as a 1–3-hours infusion
- Post cisplatin: Fluorouracil 750 mg/m² once daily given as a 24-hour continuous infusion for 5 days
- Repeat cycle every 3 weeks

Docetaxel - ADOXI

- **Dosage of Docetaxel:**
- **Head & Neck Cancer :**
 - Induction chemotherapy followed by radiotherapy : Day 1: 75 mg/m² IV infusion over 1 hour, followed by cisplatin 75 mg/m² as a 1 hour infusion:
 - Post cisplatin: Fluorouracil 750 mg/m² once daily given as a 24-hour continuous IV infusion for 5 days : Repeat cycle every 3 weeks 4 times
 - Induction chemotherapy followed by chemoradiotherapy :Day 1: 75 mg/m² IV infusion over 1 hour, followed by cisplatin 100 mg/m² as a 0.5-3 hour infusion
 - Post cisplatin: Fluorouracil 1000 mg/m² once daily given as a 24-hour continuous IV infusion from day 1 to day 4 :Repeat cycle every 3 weeks for 3 cycles
- **Prostate Cancer :**
 - 75 mg/m² IV over 1 hour every 3 weeks with daily prednisone 5 mg orally every 12 hours

Peg L-Asparaginase -Peg- Lasgen

- **Indication**

1. First Line Acute Lymphoblastic Leukemia (ALL)
2. Acute Lymphoblastic Leukaemia And Hypersensitivity To Asparaginase

- **Dosage Form & Strengths** – 3,750 International Units/5 mL (750 International Units/mL), For IM/IV administration

- **Packaging** -Vial



How Peg L-Asparaginase Works

Asparaginase's Role

Asparaginase breaks down the amino acid asparagine, which is crucial for the growth and survival of certain cancer cells.

Pegylation's Impact

Pegylation is a process that adds a polyethylene glycol (PEG) molecule to molecule to asparaginase. This makes the drug last longer in the body, body, requiring fewer doses.

Targeting Leukemia

ALL cells rely heavily on asparagine for their growth. By depleting this amino acid, amino acid, pegylated asparaginase effectively targets and weakens leukemia leukemia cells.

Peg L-Asparginase -Peg- Lasgen

- Dosage of Peg-Lasgen
- Acute Lymphoblastic Leukemia
- 2,000 international units/m² IM or IV no more frequently than q14Days

ADBIRON


Abiraterone Tablets 250mg



ADBIRON – Mechanism of Action


Primary Target

Abiraterone **targets CYP17**, a key enzyme in the production of androgens.



Lower Androgen Levels

By inhibiting CYP17, Abiraterone significantly reduces the production of androgens, specifically testosterone and DHEA.




Blocking Tumor Growth

Ultimately, Abiraterone works by preventing the growth and spread of prostate cancer cells, improving patient outcomes.

ADBIRON

Mechanism of Action



ADBIRON - Indications

- Abiraterone is a CYP17 inhibitor indicated for use in combination with prednisone for the treatment of patients with **metastatic castration-resistant prostate cancer** who have received prior chemotherapy containing docetaxel.



ADBIRON – Dosage & Administration

- Abiraterone 1,000 mg administered orally once daily in combination with prednisone 5 mg administered orally twice daily.
- Abiraterone must be taken on an empty stomach.
- No food should be consumed for at least two hours before the dose of Abiraterone is taken and for at least one hour after the dose of Abiraterone is taken.
- For patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the Abiraterone starting dose to 250 mg once daily.
- For patients who develop hepatotoxicity during treatment, hold Abiraterone until recovery.
- Retreatment may be initiated at a reduced dose.
- Abiraterone should be discontinued if patients develop severe hepatotoxicity.

Dosage and Administration

➤ Dosage

The standard adult dosage for Abiraterone is 1,000mg per day.

➤ Duration

Treatment with Abiraterone should continue until disease progression or unacceptable toxicity.

➤ Administration

Abiraterone should be taken as four 250mg tablets once daily, on an empty stomach.

Albumin Bound Paclitaxel – AB-PACLI

Indication:-

- Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
- Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
- Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.

Dosage Forms and Strengths:

A lyophilized vial of 100 mg

Packaging - vials



Albumin Bound Paclitaxel – AB-PACLI

- **Pancreatic Cancer**
 - 125 mg/m² IV infused over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle
 - Administer gemcitabine 1000 mg/m² IV infused over 30-40 minutes immediately after paclitaxel protein bound on Days 1, 8 and 15 of each 28-day cycle
- **Breast Cancer**
 - 260 mg/m² IV infused over 30 minutes q3weeks
- **Non-Small Cell Lung Cancer**
 - 100 mg/m² IV infused over 30 minutes on Days 1, 8, and 15 of each 21-day cycle, PLUS
 - Carboplatin AUC 6 mg•min/mL IV on Day 1 of each 21 day cycle immediately after paclitaxel protein bound infusion

Benefits of AB-Paclitaxel Over Conventional Therapy

Enhanced Delivery

Albumin-bound paclitaxel allows for more targeted drug delivery to tumor cells, leading to increased efficacy and reduced side effects.

Improved Solubility

Albumin-bound paclitaxel's improved solubility allows for higher doses to be administered, potentially leading to greater therapeutic benefits.

Reduced Toxicity

The albumin-bound formulation helps reduce the toxic effects associated with conventional paclitaxel, improving patient tolerability and quality of life.

Hydroxyurea Capsules - Adrea

- **Indications**:- Adrea is an antimetabolite indicated for the treatment of:
 - Resistant chronic myeloid leukemia.
 - Locally advanced squamous cell carcinomas of the head and neck, (excluding lip) in combination with concurrent chemoradiation.
- **Dosage Form** –Capsules
- **Strengths** – 500 mg
- **Packaging** - Strip



Hydroxyurea Capsule: Dosage and Administration

Condition	Dosage	Frequency
Sickle Cell Anemia	15-30 mg/kg/day	Once daily
Chronic Myelogenous Leukemia	20-40 mg/kg/day	Once daily
Other Cancers	Variable based on type of cancer	Once daily



Thank You!